The molecular and cellular heterogeneity of pancreatic ductal adenocarcinoma.
about
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genesDeciphering the link between PI3K and PAK: An opportunity to target key pathways in pancreatic cancer?Identification of KCa3.1 Channel as a Novel Regulator of Oxidative Phosphorylation in a Subset of Pancreatic Carcinoma Cell LinesSweating the small stuff: microRNAs and genetic changes define pancreatic cancer.RON is not a prognostic marker for resectable pancreatic cancer.Pancreatic cancer genomics: where can the science take us?Comparative proteomic profiling of pancreatic ductal adenocarcinoma cell lines.CD109 Overexpression in Pancreatic Cancer Identified by Cell-Surface Glycoprotein Capture.The anti-tumor efficacy of 2-deoxyglucose and D-allose are enhanced with p38 inhibition in pancreatic and ovarian cell lines.Pancreatic cancer and FOLFIRINOX: a new era and new questions.The indolent nature of pulmonary metastases from ductal adenocarcinoma of the pancreasPrognosis Relevance of Serum Cytokines in Pancreatic Cancer.Characteristics of Tumor Infiltrating Lymphocyte and Circulating Lymphocyte Repertoires in Pancreatic Cancer by the Sequencing of T Cell Receptors.Amplified centrosomes may underlie aggressive disease course in pancreatic ductal adenocarcinoma.A pancreatic ductal adenocarcinoma subpopulation is sensitive to FK866, an inhibitor of NAMPT.Construction and analysis of dysregulated lncRNA-associated ceRNA network identified novel lncRNA biomarkers for early diagnosis of human pancreatic cancer.Clinical and molecular characterization of HER2 amplified-pancreatic cancer.Understanding pancreatic cancer genomes.Stem cell-directed therapies in pancreatic cancer.The conflicting roles of tumor stroma in pancreatic cancer and their contribution to the failure of clinical trials: a systematic review and critical appraisal.Evolution of targeted therapies in cancer: opportunities and challenges in the clinic.Recapitulation of complex transport and action of drugs at the tumor microenvironment using tumor-microenvironment-on-chip.HSP90 is a promising target in gemcitabine and 5-fluorouracil resistant pancreatic cancer.Measurement of protein kinase B activity in single primary human pancreatic cancer cells.SOX15 is a candidate tumor suppressor in pancreatic cancer with a potential role in Wnt/β-catenin signaling.Quantitative assessment of pancreatic cancer precursor lesions in IHC-stained tissue with a tissue image analysis platform.Combined targeting of TGF-β, EGFR and HER2 suppresses lymphangiogenesis and metastasis in a pancreatic cancer model.Novel cancer drivers: mining the kinome.The personalized medicine for pancreatic ductal adenocarcinoma patients: The oncologist perspective.Pancreas specific expression of oncogenes in a porcine model.Phase II, randomized, biomarker identification trial (MARK) for erlotinib in patients with advanced pancreatic carcinoma.Developing a genetic signature to predict drug response in ovarian cancer.Pancreatic cancer subtypes: a roadmap for precision medicineNovel three‑lncRNA signature predicts survival in patients with pancreatic cancer
P2860
Q24595981-3DA9779C-9D65-4963-8278-483ED90B568AQ28079848-9A20C8E9-BB24-499E-8BF9-558C8F39A860Q28553394-D8F7AD7D-DFEB-4AD1-B07C-A5FF9734A54CQ33862088-733F5B0C-4F0C-4003-96CE-545FDB1D42D2Q34408923-A2CDC890-9370-47CF-AB25-2A436C71EBA8Q34447458-A15383EF-8F21-4415-A5BA-9F8563BC5D86Q34768090-7ED07F9F-E53D-48A4-A3FC-B2473AA528CEQ35017547-192614F3-9824-4E8D-9CB8-8AC09D303207Q35339214-E9752FE1-4B5E-4C3D-A4CA-24C760828625Q35755386-E8F0A7B9-DD2B-41CD-9DA3-A1C3809173A1Q35875608-694B5607-604A-4BA4-B573-0784CE01DB81Q35963911-397B0D99-1E6E-4B03-A4FD-A79D9A82A1D6Q36017958-DADA871C-B056-4C5C-8CCE-044DEEED4085Q36189152-434DBE00-B403-4066-ACED-FB5E90D92D62Q37619827-B3506E36-63F3-4B1A-AE0C-04FDCDF04043Q37636634-B573E535-65F1-47C7-88EB-F73A63B4D2A2Q37690146-002485C1-BF50-49C4-97ED-49A1ADD5FA45Q38105473-6CADE0A2-5836-436F-98D1-779885C9B555Q38170621-F85934EA-C29E-4AFC-9D89-DE384371BCA1Q38310416-19AFE185-41BF-4AD2-A4C3-2A27C63764D9Q38319572-CD0C4BBC-7F4E-4136-9370-9A55DF865402Q38674749-7E6ECEB3-F4D1-421A-AFE8-C309BE5C6BC3Q38729418-45BB9C7C-A6BC-4CB7-8622-193A007F9EB5Q39005983-AB2B2378-4869-46B9-B4A4-FB3D9C8284EAQ39210861-0D435DE8-8BBF-4DF8-90D2-EF5FF901B7D7Q39254907-64CCE843-1678-4BBC-BA4B-C1A0D3F4ADA4Q39706220-1BD40702-99C5-451D-811E-311973CBB61AQ42058226-2A08FDDA-8737-415D-94C7-F72CB7D69647Q49284538-A5BAE1CC-ACF3-407B-8D2F-4C662A1F967DQ50203736-A870942F-7CE1-42E5-BBAB-0C17B63912F5Q54352754-6CF7BF9B-CC17-4698-9E98-2D395014D68CQ55028564-FBF9E307-8B98-4DE9-AFFE-27BB08FB7E2CQ58146806-CD227675-3DB2-4A72-A9E8-512C627D7041Q58786413-3345E94E-C293-41AF-A82A-789B9248E2E8
P2860
The molecular and cellular heterogeneity of pancreatic ductal adenocarcinoma.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
The molecular and cellular heterogeneity of pancreatic ductal adenocarcinoma.
@en
The molecular and cellular heterogeneity of pancreatic ductal adenocarcinoma.
@nl
type
label
The molecular and cellular heterogeneity of pancreatic ductal adenocarcinoma.
@en
The molecular and cellular heterogeneity of pancreatic ductal adenocarcinoma.
@nl
prefLabel
The molecular and cellular heterogeneity of pancreatic ductal adenocarcinoma.
@en
The molecular and cellular heterogeneity of pancreatic ductal adenocarcinoma.
@nl
P2860
P1476
The molecular and cellular heterogeneity of pancreatic ductal adenocarcinoma.
@en
P2093
Nardin Samuel
Thomas J Hudson
P2860
P2888
P356
10.1038/NRGASTRO.2011.215
P407
P577
2011-12-20T00:00:00Z